Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Esophageal Neoplasms × pertuzumab × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 59 Ovarian Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 3 Inflammatory Breast Neoplasms 3 Breast Neoplasms, Male 3 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Ductal, Breast 2 Urinary Bladder Neoplasms 1 Patient Preference 1 Neoplasms, Unknown Primary 1 Metastatic HER2-Positive Breast Cancer 1 Lung Neoplasms 1 Her2-Positive Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Elderly Metastatic Breast Cancer Population 1 Carcinoma, Neuroendocrine 1 Biliary Tract Neoplasms 1

Interventions

Cisplatin 85 Fluorouracil 70 Radiotherapy 59 Paclitaxel 53 Docetaxel 46 Oxaliplatin 44 Irinotecan 39 Leucovorin 31 Capecitabine 28 Carboplatin 21 Surgical Procedures, Operative 19 Radiation 18 Esophagectomy 18 Bevacizumab 15 pembrolizumab 13 Neoadjuvant Therapy 13 Cetuximab 13 Epirubicin 10 Drug Therapy 10 S 1 (combination) 8 Magnetic Resonance Spectroscopy 8 Gemcitabine 8 Chemotherapy, Adjuvant 8 Trastuzumab 7 Erlotinib Hydrochloride 7 Surveys and Questionnaires 6 Panitumumab 6 Nivolumab 6 Chemoradiotherapy 6 Albumin-Bound Paclitaxel 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02120911 2020-07-01

TRAP

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡